KZIA

Kazia Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth↑ 7/10
  • Momentum↑ 5/10
Kazia Therapeutics sales and earnings growth
KZIA Growth
Good
  • Revenue Y/Y↑ 182800.00%
  • EPS Y/Y↑ 66.34%
  • FCF Y/Y↑ 12.39%
Kazia Therapeutics gross and profit margin trends
KZIA Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1131.90%
  • ROIC↑ 186.80%
Kazia Therapeutics net debt vs free cash flow
KZIA Risk
Great
  • Debt / Equity↓ -0.4
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Kazia Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗